These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 33732882)

  • 1. Elevated soluble urokinase plasminogen activator receptor serum levels indicate poor survival following transarterial chemoembolization therapy for hepatic malignancies: An exploratory analysis.
    Loosen SH; Schulze-Hagen M; Vucur M; Gorgulho J; Paffenholz P; Benz F; Mohr R; Demir M; Wree A; Kuhl C; Trautwein C; Tacke F; Bruners P; Luedde T; Roderburg C
    JGH Open; 2021 Mar; 5(3):356-363. PubMed ID: 33732882
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating levels of soluble urokinase plasminogen activator receptor predict outcome after resection of biliary tract cancer.
    Loosen SH; Breuer A; Tacke F; Kather JN; Gorgulho J; Alizai PH; Bednarsch J; Roeth AA; Lurje G; Schmitz SM; Brozat JF; Paffenholz P; Vucur M; Ritz T; Koch A; Trautwein C; Ulmer TF; Roderburg C; Longerich T; Neumann UP; Luedde T
    JHEP Rep; 2020 Apr; 2(2):100080. PubMed ID: 32140677
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Macrophage migration inhibitory factor predicts an unfavorable outcome after transarterial chemoembolization for hepatic malignancies.
    Wirtz TH; Loosen SH; Schulze-Hagen M; Gorgulho J; Kandler J; Joerdens M; Demir M; Mohr R; Bruners P; Kuhl C; Trautwein C; Berres ML; Tacke F; Luedde T; Roderburg C
    Clin Transl Sci; 2021 Sep; 14(5):1853-1863. PubMed ID: 33787014
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum Levels of Soluble Urokinase Plasminogen Activator Receptor Predict Tumor Response and Outcome to Immune Checkpoint Inhibitor Therapy.
    Loosen SH; Gorgulho J; Jördens MS; Schulze-Hagen M; Beier F; Vucur M; Schneider AT; Koppe C; Mertens A; Kather JN; Tacke F; Keitel V; Brümmendorf TH; Roderburg C; Luedde T
    Front Oncol; 2021; 11():646883. PubMed ID: 33869041
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum levels of soluble urokinase plasminogen activator receptor (suPAR) predict outcome after resection of colorectal liver metastases.
    Loosen SH; Tacke F; Binnebosel M; Leyh C; Vucur M; Heitkamp F; Schoening W; Ulmer TF; Alizai PH; Trautwein C; Koch A; Longerich T; Roderburg C; Neumann UP; Luedde T
    Oncotarget; 2018 Jun; 9(43):27027-27038. PubMed ID: 29930748
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High baseline soluble urokinase plasminogen activator receptor (suPAR) serum levels indicate adverse outcome after resection of pancreatic adenocarcinoma.
    Loosen SH; Tacke F; Püthe N; Binneboesel M; Wiltberger G; Alizai PH; Kather JN; Paffenholz P; Ritz T; Koch A; Bergmann F; Trautwein C; Longerich T; Roderburg C; Neumann UP; Luedde T
    Carcinogenesis; 2019 Aug; 40(8):947-955. PubMed ID: 30805627
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The prognostic value of plasma soluble urokinase plasminogen activator receptor (suPAR) levels in stage III ovarian cancer patients.
    Begum FD; Høgdall CK; Kjaer SK; Christensen L; Blaakaer J; Bock JE; Glud E; Høyer-Hansen G; Ring-Larsen H; Høgdall EV
    Anticancer Res; 2004; 24(3b):1981-5. PubMed ID: 15274388
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating soluble urokinase plasminogen activator is elevated in patients with chronic liver disease, discriminates stage and aetiology of cirrhosis and predicts prognosis.
    Zimmermann HW; Koch A; Seidler S; Trautwein C; Tacke F
    Liver Int; 2012 Mar; 32(3):500-9. PubMed ID: 22098627
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Prognostic Significance of Soluble Urokinase Plasminogen Activator Receptor in Acute Myeloid Leukemia.
    Erkut N; Menteşe A; Özbaş HM; Ermantaş N; Sümer A; Örem A; Sönmez M
    Turk J Haematol; 2016 Jun; 33(2):135-40. PubMed ID: 26376588
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Soluble urokinase plasminogen activator receptor is compartmentally regulated in decompensated cirrhosis and indicates immune activation and short-term mortality.
    Zimmermann HW; Reuken PA; Koch A; Bartneck M; Adams DH; Trautwein C; Stallmach A; Tacke F; Bruns T
    J Intern Med; 2013 Jul; 274(1):86-100. PubMed ID: 23432143
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Plasma Soluble Urokinase Plasminogen Activator Receptor Is Related to Disease Activity of Patients with ANCA-Associated Vasculitis.
    Huang F; Li Y; Xu R; Cheng A; Lv Y; Liu Q
    Mediators Inflamm; 2020; 2020():7850179. PubMed ID: 32322165
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum soluble urokinase plasminogen activator receptor as a screening test for the early diagnosis of hepatocellular carcinoma.
    Chounta A; Ellinas C; Tzanetakou V; Pliarhopoulou F; Mplani V; Oikonomou A; Leventogiannis K; Giamarellos-Bourboulis EJ
    Liver Int; 2015 Feb; 35(2):601-7. PubMed ID: 25348952
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exploring the clinical value of preoperative serum gamma-glutamyl transferase levels in the management of patients with hepatocellular carcinoma receiving postoperative adjuvant transarterial chemoembolization.
    Ke Q; Xiang F; Xiao C; Huang Q; Liu X; Zeng Y; Wang L; Liu J
    BMC Cancer; 2021 Oct; 21(1):1117. PubMed ID: 34663242
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Soluble urokinase plasminogen activator receptor levels predict survival in patients with portal hypertension undergoing TIPS.
    Loosen SH; Benz F; Mohr R; Reuken PA; Wirtz TH; Junker L; Jansen C; Meyer C; Praktiknjo M; Wree A; Reißing J; Demir M; Gu W; Vucur M; Schierwagen R; Stallmach A; Kunstein A; Bode J; Trautwein C; Tacke F; Luedde T; Bruns T; Trebicka J; Roderburg C
    JHEP Rep; 2024 May; 6(5):101054. PubMed ID: 38681861
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating soluble urokinase plasminogen activator receptor is stably elevated during the first week of treatment in the intensive care unit and predicts mortality in critically ill patients.
    Koch A; Voigt S; Kruschinski C; Sanson E; Dückers H; Horn A; Yagmur E; Zimmermann H; Trautwein C; Tacke F
    Crit Care; 2011; 15(1):R63. PubMed ID: 21324198
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Soluble Urokinase Plasminogen Activator Receptor (suPAR) Concentrations are Elevated in Patients with Neuroendocrine Malignancies.
    Özdirik B; Stueven A; Knorr J; Geisler L; Mohr R; Demir M; Hellberg T; Loosen SH; Benz F; Wiedenmann B; Tacke F; Wree A; Jann H; Roderburg C
    J Clin Med; 2020 May; 9(6):. PubMed ID: 32486367
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sarcopenia Is a Negative Prognostic Factor in Patients Undergoing Transarterial Chemoembolization (TACE) for Hepatic Malignancies.
    Loosen SH; Schulze-Hagen M; Bruners P; Tacke F; Trautwein C; Kuhl C; Luedde T; Roderburg C
    Cancers (Basel); 2019 Oct; 11(10):. PubMed ID: 31597337
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma urokinase receptor levels in patients with colorectal cancer: relationship to prognosis.
    Stephens RW; Nielsen HJ; Christensen IJ; Thorlacius-Ussing O; Sørensen S; Danø K; Brünner N
    J Natl Cancer Inst; 1999 May; 91(10):869-74. PubMed ID: 10340907
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic significance of soluble urokinase plasminogen activator receptor in serum and cytosol of tumor tissue from patients with primary breast cancer.
    Riisbro R; Christensen IJ; Piironen T; Greenall M; Larsen B; Stephens RW; Han C; Høyer-Hansen G; Smith K; Brünner N; Harris AL
    Clin Cancer Res; 2002 May; 8(5):1132-41. PubMed ID: 12006529
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The significance of serum urokinase plasminogen activation receptor (suPAR) in the diagnosis and follow-up of febrile neutropenic patients with hematologic malignancies.
    Kaya S; Köksal I; Menteşe A; Sönmez M; Sümer A; Yıldırım SS; Yılmaz G
    Int J Infect Dis; 2013 Nov; 17(11):e1056-9. PubMed ID: 23742830
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.